ASX 200 Undervalued Picks: Corporate Travel and PolyNovo Stand Firm Amid Market Volatility

Highlights

• Corporate Travel Management highlighted for stability across key global markets

• PolyNovo continues strategic growth through international medical device distribution

• Market uncertainty drives attention to companies with solid fundamentals

The Australian equity market, led by the ASX 200, has experienced fluctuating sessions recently amid rising geopolitical tensions and a surge in global oil prices. While sectors such as Energy have demonstrated resilience, others like Industrials and IT have faced significant downward pressure. In this climate, attention has turned to companies demonstrating robust financials and steady operational performance. Among these, Corporate Travel Management and PolyNovo Limited have surfaced as names maintaining momentum through macroeconomic instability.

Corporate Travel Management Expands Through Multinational Reach

Corporate Travel Management Ltd (ASX:CTD), a company engaged in global travel services, continues to operate across key regions including Australia and New Zealand, North America, Asia, and Europe. The company is structured to deliver tailored travel management programs, providing it with a diversified revenue base and strategic footprint.

CTD’s regional distribution reflects broad-based demand, with revenue streams emerging across both the domestic and international corporate travel sectors. Its model enables the business to adapt to shifting travel trends and corporate activity levels in different parts of the world. Leadership transitions are underway with Jo Sully slated to take on the Australia and New Zealand CEO role by mid-2025. The development is anticipated to align with CTD’s expansion efforts and operational evolution.

The company remains active in advancing digital transformation across its platforms, focused on automation and improved user experience for corporate clients. This positioning underlines its responsiveness to sector needs and long-term service adaptability.

PolyNovo Advances Global Reach in Medical Device Innovation

PolyNovo Ltd (ASX:PNV), a biotech manufacturer specialising in biodegradable medical solutions, operates in markets spanning the United States, Australia, and New Zealand, with international reach extending across Europe and Asia. The company’s NovoSorb® technology forms the backbone of its wound treatment and surgical product lines, utilised in both hospital and trauma care settings.

PolyNovo’s ongoing growth is underpinned by an expanding product range and investments in clinical trials and regulatory clearances. The company continues to build its presence in international healthcare systems, establishing strategic distribution partnerships and reinforcing its commercial footprint.

Its operations reflect the consistent application of innovation to address global health needs. With regulatory milestones achieved in key jurisdictions, PolyNovo’s pipeline supports its ambition of becoming a leader in synthetic medical polymers.

Broader Trends Highlight Value in Fundamentals

While broader markets have oscillated amid geopolitical and inflationary pressures, these two ASX-listed companies exhibit characteristics valued in uncertain periods. Their cross-regional operations, operational transparency, and leadership focus contribute to their ability to weather market challenges. In particular, consistency in earnings and efficient capital management continue to attract attention from market observers.